全文获取类型
收费全文 | 9041篇 |
免费 | 977篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 300篇 |
妇产科学 | 189篇 |
基础医学 | 1218篇 |
口腔科学 | 284篇 |
临床医学 | 993篇 |
内科学 | 1759篇 |
皮肤病学 | 92篇 |
神经病学 | 877篇 |
特种医学 | 563篇 |
外科学 | 1179篇 |
综合类 | 328篇 |
一般理论 | 7篇 |
预防医学 | 960篇 |
眼科学 | 272篇 |
药学 | 543篇 |
中国医学 | 3篇 |
肿瘤学 | 407篇 |
出版年
2021年 | 116篇 |
2020年 | 106篇 |
2019年 | 148篇 |
2018年 | 158篇 |
2017年 | 131篇 |
2016年 | 109篇 |
2015年 | 138篇 |
2014年 | 185篇 |
2013年 | 326篇 |
2012年 | 388篇 |
2011年 | 419篇 |
2010年 | 227篇 |
2009年 | 225篇 |
2008年 | 366篇 |
2007年 | 394篇 |
2006年 | 383篇 |
2005年 | 370篇 |
2004年 | 352篇 |
2003年 | 277篇 |
2002年 | 312篇 |
2001年 | 283篇 |
2000年 | 272篇 |
1999年 | 260篇 |
1998年 | 126篇 |
1997年 | 116篇 |
1996年 | 136篇 |
1995年 | 118篇 |
1994年 | 107篇 |
1993年 | 109篇 |
1992年 | 213篇 |
1991年 | 190篇 |
1990年 | 214篇 |
1989年 | 231篇 |
1988年 | 224篇 |
1987年 | 175篇 |
1986年 | 175篇 |
1985年 | 198篇 |
1984年 | 132篇 |
1983年 | 130篇 |
1982年 | 101篇 |
1981年 | 82篇 |
1979年 | 118篇 |
1978年 | 101篇 |
1977年 | 104篇 |
1976年 | 83篇 |
1975年 | 74篇 |
1974年 | 71篇 |
1973年 | 95篇 |
1972年 | 87篇 |
1971年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
2.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
3.
M.S. Iqbal G. Vashisht R. McMenemin P. Atherton F. McDonald T. Simmons A. Bradshaw J. Kovarik H. Turnbull L. Dodd P. Mulvenna A. Greystoke 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):e1-e10
Aims
Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.Materials and methods
One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.Results
In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.Conclusion
Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial. 相似文献4.
5.
6.
7.
8.
Sarah E. R. Bailey Gary A. Abel Alex Atkins Rachel Byford Sarah-Jane Davies Joe Mays Timothy J. McDonald Jon Miller Catherine Neck John Renninson Paul Thomas Fiona M. Walter Sarah Warren Willie Hamilton 《British journal of cancer》2021,124(7):1231
Background The faecal immunochemical test (FIT) was introduced to triage patients with low-risk symptoms of possible colorectal cancer in English primary care in 2017, underpinned by little primary care evidence.Methods All healthcare providers in the South West of England (population 4 million) participated in this evaluation. 3890 patients aged ≥50 years presenting in primary care with low-risk symptoms of colorectal cancer had a FIT from 01/06/2018 to 31/12/2018. A threshold of 10 μg Hb/g faeces defined a positive test.Results Six hundred and eighteen (15.9%) patients tested positive; 458 (74.1%) had an urgent referral to specialist lower gastrointestinal (GI) services within three months. Forty-three were diagnosed with colorectal cancer within 12 months. 3272 tested negative; 324 (9.9%) had an urgent referral within three months. Eight were diagnosed with colorectal cancer within 12 months. Positive predictive value was 7.0% (95% CI 5.1–9.3%). Negative predictive value was 99.8% (CI 99.5–99.9%). Sensitivity was 84.3% (CI 71.4–93.0%), specificity 85.0% (CI 83.8–86.1%). The area under the ROC curve was 0.92 (CI 0.86–0.96). A threshold of 37 μg Hb/g faeces would identify patients with an individual 3% risk of cancer.Conclusions FIT performs exceptionally well to triage patients with low-risk symptoms of colorectal cancer in primary care; a higher threshold may be appropriate in the wake of the COVID-19 crisis.Subject terms: Digestive signs and symptoms, Diagnostic markers, Gastrointestinal cancer 相似文献
9.